Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of stock options to 10 newly hired employees on March 19, 2023. A total of 32,700 shares were offered as an inducement for employment, under the 2021 Inducement Equity Incentive Plan. The stock options have an exercise price of $25.62 per share, matching the stock's closing price on March 17, 2023. The options have a ten-year term and will vest over four years, with different vesting schedules for U.S. and international employees. This initiative reflects Schrödinger's commitment to attract talent in the competitive biopharmaceutical sector.

Schrödinger, Inc. (Nasdaq: SDGR) reported a 31% increase in total revenue for 2022, reaching $181.0 million. In Q4 2022, total revenue rose by 23% to $56.8 million, driven by a 24% increase in software revenue, totaling $47.8 million. Drug discovery revenue nearly doubled year-over-year to $45.4 million. The company expects continued growth in 2023, projecting software revenue growth of 13-17% and drug discovery revenue of $70-90 million. Operating expenses for 2022 stood at $247.8 million, with a net loss of $149.2 million. Despite challenges, Schrödinger is advancing its drug pipeline and improving financial metrics.

Schrödinger, Inc. (Nasdaq: SDGR) announced on February 15, 2023 the grant of stock options for 45,600 shares to 11 new employees, including international hires. This inducement is part of the company’s 2021 Inducement Equity Incentive Plan and follows Nasdaq Listing Rule 5635(c)(4). Each option is priced at $24.39, the closing stock price on the grant date. Options vest over four years, with 25% vesting after one year and the remainder based on service duration. Schrödinger leverages its physics-based computational platform for drug discovery and materials applications, supporting a global clientele while employing over 800 people worldwide.

Schrödinger Inc. (Nasdaq: SDGR) reported a cash distribution of $111.3 million from Nimbus Therapeutics related to Takeda's acquisition of Nimbus Lakshmi, which includes the TYK2 inhibitor NDI-034858. This drug is advancing towards pivotal trials after positive Phase 2b results in psoriasis. The company anticipates an additional $36 million distribution in Q2 2023, totaling approximately $147.3 million. CEO Ramy Farid highlighted the successful collaboration with Nimbus since its founding in 2009, underscoring the validation of their computational methods to discover innovative medicines.

Schrödinger (Nasdaq: SDGR) will announce its fourth quarter and full-year 2022 financial results on February 28, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Interested participants can access the live webcast under 'News & Events' on Schrödinger's investor website. The company leverages its physics-based computational platform to revolutionize drug and material discoveries, with partnerships worldwide. Founded in 1990, Schrödinger employs over 800 staff and collaborates in more than 70 countries.

Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.

Schrödinger (Nasdaq: SDGR) will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET. The presentation details will be available under the "News & Events" section on their website and archived for seven days. Schrödinger is known for its innovative physics-based computational platform that accelerates the discovery of novel molecules for drug and material development. Founded in 1990, the company has over 800 employees and partners globally in over 70 countries.

Schrödinger, Inc. (Nasdaq: SDGR) recently announced the granting of non-statutory stock options for 14,300 shares and restricted stock units (RSUs) for 4,350 shares to new employees as part of their 2021 Inducement Equity Incentive Plan. The stock options, priced at $23.83 per share, will vest over four years with specific conditions based on the employees' service duration. RSUs will also vest over four years. This move aims to attract talent and enhance the company's growth in therapeutic and materials discovery, leveraging its advanced computational platform.

Schrödinger (Nasdaq: SDGR) announced significant developments, including an expanded collaboration with Bristol Myers Squibb to target neurology and a new partnership with Otsuka Pharmaceutical for CNS diseases. The company reported progress on its LRRK2 inhibitor program aimed at Parkinson's disease and emphasized its 2022 achievements, such as FDA clearance for SGR-1505 and multiple new drug discovery collaborations. For 2023, Schrödinger aims to advance its clinical trials and expand its collaborative drug discovery efforts, with financial results scheduled for February 28, 2023.